Health411-Cancer Therapeutics with Greg Bosch

In this episode of Health411, host Dr. Jonathan Karp and producer Daniel Geller discuss Panavance Therapeutics with Chairman and CEO Greg Bosch. Panavance is focused on the compound GP-2250, a molecule with broad applications in cancer treatment. During the interview, Mr. Bosch elaborates on the groundbreaking potential of GP-2250, explaining how it targets specific cancer cells while minimizing damage to healthy tissue. He also shared insights into Panavance's rigorous clinical trials and its commitment to advancing personalized therapies for cancer patients. Tune in to learn more about the promising future of GP-2250 and its potential to revolutionize cancer treatment.